A Phase 1 interventional study of RO7171009 in Geographic Atrophy, sponsored by Genentech, Inc.. Completed at 13 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by Genentech, Inc. · Phase 1, Interventional, and Treatment
This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.
Exclusion Criteria:
Ocular Exclusion Criteria, Study Eye:
Ocular Exclusion Criteria (Both Eyes):
Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
Drug: RO7171009
Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
Drug: RO7171009
Patients will receive RO7171009 via ITV injection.
Safety and Tolerability of the Study Drug: Rate of Adverse Events
Time frame: Through study completion or early study discontinuation (overall 12-20 weeks)
Serum Concentration of RO7171009
Time frame: Through study completion or early study discontinuation (overall 12-20 weeks)
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genentech, Inc.